Non-Insulin Therapies for Diabetes Market Set to Expand Saliently at a Robust CAGR during the Forecast Period 2018-2026

1. Non-Insulin Therapies for Diabetes Market to Expand Steadily in the Coming Years till 2018-2026 Non-Insulin Therapies for Diabetes Market, by Drug Class (Biguanides, Sulfonylureas Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, GLP-1 Analogs, and Sodium-glucose co-transporter-2 (SGLT2) inhibitors), by Route of Administration (Oral and Injectable), by Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and by Region – Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026 Non-insulin therapies are mostly used in type 2 diabetes patients, where body either does not produce enough insulin or is unable to efectiiely use the insulin it produces. Non-insulin-based medication works with diferent mechanism of action to reduce blood glucose leiel and maintain it for optimum glycemic control. For instance, some agents increase the insulin release from pancreatic cells (Sulfonylureas), some agents increase glucose uptake by periphery and reduces hepatic glucose output (Biguanides), some agents slow down digestion of starch in small intestine (alpha glucosidase inhibitors), and some medication reduces post meal sugar by blocking certain enzymes (Incretin mimetics). Download PDF Brochure of Market Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2042 Non-Insulin Therapies for Diabetes Market Dynamics Increasing global incidence and preialence of diabetes is expected to fuel growth of the non- insulin therapies for diabetes market. Non-insulin therapies are mainly used in type 2 diabetes, which accounts for around 90% of the global diabetes cases. According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, worldwide preialence of diabetic patients was around 425 million, of which around 400 million patients were sufering from type 2 diabetes. As per the World Health Organization (WHO) 2017 report, diabetes is one of the top 3 causes of death among non-communicable diseases worldwide, with 114.4 million cases in China, 72.9 million cases in India, and 30.2 million cases in the U.S. Browse more about the Deep Brain Stimulation Devices Market Study: https://www.coherentmarketinsights.com/insight/request-customization/2042 Market Players

2. AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, F. Hofmann-La Roche Ltd., Janssen Pharmaceuticals, Merck and Company, Noiartis AG, Noio Nordisk, Pfzer, Sanof Aientis, and Takeda Pharmaceuticals. Non-insulin Therapies for Diabetes Market: Taxonomy On the basis of drug class, the global non-insulin therapies for diabetes market is segmented into: •Biguanides •Sulfonylureas •Thiazolidinedione’s •Alpha-Glucosidase Inhibitors •DPP-4 Inhibitors •GLP-1 Analogs •Sodium-glucose co-transporter-2 (SGLT2) inhibitors On the basis of route of administration, the global non-insulin therapies for diabetes market is segmented into: •Oral •Intramuscular On the basis of distribution channel, the global non-insulin therapies for diabetes market is segmented into: •Retail Pharmacy •Hospital Pharmacy •Online Pharmacy On the basis of region, the global non-insulin therapies for diabetes market is segmented into: •North America •Latin America •Europe •Asia Pacifc •Middle East •Africa

3. About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com